Autolus Therapeutics plc (NASDAQ:AUTL) Shares Bought by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd boosted its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,250,000 shares of the company's stock after acquiring an additional 250,000 shares during the quarter. Autolus Therapeutics comprises about 4.8% of TFG Asset Management GP Ltd's investment portfolio, making the stock its 4th biggest holding. TFG Asset Management GP Ltd owned 3.10% of Autolus Therapeutics worth $19,388,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Jane Street Group LLC purchased a new stake in Autolus Therapeutics in the 4th quarter worth approximately $26,000. Barclays PLC boosted its position in Autolus Therapeutics by 1,094.3% during the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC purchased a new position in Autolus Therapeutics in the fourth quarter valued at about $35,000. Arkadios Wealth Advisors acquired a new position in Autolus Therapeutics in the 4th quarter worth about $47,000. Finally, Daiwa Securities Group Inc. raised its stake in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares in the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Truist Financial cut their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Wells Fargo & Company cut their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 10th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics has a consensus rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Stock Down 0.3%

Autolus Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $1.53. 529,317 shares of the company were exchanged, compared to its average volume of 1,656,606. The company has a market capitalization of $405.87 million, a PE ratio of -1.26 and a beta of 1.77. Autolus Therapeutics plc has a 1-year low of $1.11 and a 1-year high of $5.00. The business has a fifty day moving average of $1.43 and a 200 day moving average of $2.09.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. Research analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.